Ellen F Eaton1, Ashutosh Tamhane1, Thibaut Davy-Mendez2, William C Mathews3, Richard D Moore4, Michael S Saag1, Michael J Mugavero1. 1. Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama. 2. Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 3. Division of Infectious Diseases, University of San Diego Health System, San Diego, California. 4. Johns Hopkins University, Division of Infectious Diseases, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: To evaluate the real world durability of contemporary ART for treatment-naïve people living with HIV (PLWH). DESIGN: A retrospective follow-up study in a multisite cohort. METHODS: This study of the CNICS (CFAR Network of Integrated Clinical Systems) cohort integrates data from eight Center for AIDS Research (CFARs). PLWH initiating ART between 2007 and 2014 were included. Durability was defined as time from the initiation until discontinuation/modification using Kaplan-Meier survival curves. Cox Proportional Hazards measured associations with various sociodemographic and clinical characteristics. RESULTS: Among 5373 PLWH, the initial regimen was modified in 2285 (43%) patients. Efavirenz/emtricitabine/tenofovir (n = 2173, 40%) was the most commonly prescribed initial ART regimen; elvitegravir/cobicistat/emtricitabine/tenofovir became more common after 2012. Median durability for all regimens was 48.6 months. There were statistically significant differences in median durability for NNRTI, InSTI, and protease inhibitor-based regimens, which lasted 61, 44, and 32 months, respectively. Female sex (aHR = 1.4; 95% CI 1.2-1.6), intravenous drug use (aHR = 1.6; 95% CI 1.3-1.9), and CD4 cell count less than 200 cells/μl (aHR = 1.2; 95% CI 1.1-1.3) were significantly associated with regimen modification. Compared with InSTI, those receiving an InSTI/protease inhibitor (aHR = 2.7; 95% CI 2.0-3.7) or protease inhibitor-based ART (aHR = 1.9; 95% CI 1.6-2.2) were significantly more likely to be modified; but those receiving NNRTI (aHR = 1.1; 95% CI 0.9-1.3) were not. CONCLUSION: In treatment-naive PLWH, NNRTI and InSTI-based ART were most durable, relative to protease inhibitor and InSTI/protease inhibitor-based ART, and were least likely to be modified/discontinued. A greater understanding of reasons for regimen modification/discontinuation is needed to analyze contemporary regimen durability.
OBJECTIVE: To evaluate the real world durability of contemporary ART for treatment-naïve people living with HIV (PLWH). DESIGN: A retrospective follow-up study in a multisite cohort. METHODS: This study of the CNICS (CFAR Network of Integrated Clinical Systems) cohort integrates data from eight Center for AIDS Research (CFARs). PLWH initiating ART between 2007 and 2014 were included. Durability was defined as time from the initiation until discontinuation/modification using Kaplan-Meier survival curves. Cox Proportional Hazards measured associations with various sociodemographic and clinical characteristics. RESULTS: Among 5373 PLWH, the initial regimen was modified in 2285 (43%) patients. Efavirenz/emtricitabine/tenofovir (n = 2173, 40%) was the most commonly prescribed initial ART regimen; elvitegravir/cobicistat/emtricitabine/tenofovir became more common after 2012. Median durability for all regimens was 48.6 months. There were statistically significant differences in median durability for NNRTI, InSTI, and protease inhibitor-based regimens, which lasted 61, 44, and 32 months, respectively. Female sex (aHR = 1.4; 95% CI 1.2-1.6), intravenous drug use (aHR = 1.6; 95% CI 1.3-1.9), and CD4 cell count less than 200 cells/μl (aHR = 1.2; 95% CI 1.1-1.3) were significantly associated with regimen modification. Compared with InSTI, those receiving an InSTI/protease inhibitor (aHR = 2.7; 95% CI 2.0-3.7) or protease inhibitor-based ART (aHR = 1.9; 95% CI 1.6-2.2) were significantly more likely to be modified; but those receiving NNRTI (aHR = 1.1; 95% CI 0.9-1.3) were not. CONCLUSION: In treatment-naive PLWH, NNRTI and InSTI-based ART were most durable, relative to protease inhibitor and InSTI/protease inhibitor-based ART, and were least likely to be modified/discontinued. A greater understanding of reasons for regimen modification/discontinuation is needed to analyze contemporary regimen durability.
Authors: James A McKinnell; James H Willig; Andrew O Westfall; Christa Nevin; Jeroan J Allison; James L Raper; Michael J Mugavero; Michael S Saag Journal: AIDS Patient Care STDS Date: 2010-02 Impact factor: 5.078
Authors: P T Nieuwkerk; M A Sprangers; D M Burger; R M Hoetelmans; P W Hugen; S A Danner; M E van Der Ende; M M Schneider; G Schrey; P L Meenhorst; H G Sprenger; R H Kauffmann; M Jambroes; M A Chesney; F de Wolf; J M Lange Journal: Arch Intern Med Date: 2001-09-10
Authors: Hans-Jürgen Stellbrink; Chloe Orkin; Jose Ramon Arribas; Juliet Compston; Jan Gerstoft; Eric Van Wijngaerden; Adriano Lazzarin; Giuliano Rizzardini; Herman G Sprenger; John Lambert; Gunta Sture; David Leather; Sara Hughes; Patrizia Zucchi; Helen Pearce Journal: Clin Infect Dis Date: 2010-10-15 Impact factor: 9.079
Authors: Sharon L Walmsley; Antonio Antela; Nathan Clumeck; Dan Duiculescu; Andrea Eberhard; Felix Gutiérrez; Laurent Hocqueloux; Franco Maggiolo; Uriel Sandkovsky; Catherine Granier; Keith Pappa; Brian Wynne; Sherene Min; Garrett Nichols Journal: N Engl J Med Date: 2013-11-07 Impact factor: 91.245
Authors: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Lindsay S Robison; Andrew O Westfall; Michael J Mugavero; Mirjam C Kempf; Stephen R Cole; Jeroan J Allison; James H Willig; James L Raper; C Mel Wilcox; Michael S Saag Journal: AIDS Res Hum Retroviruses Date: 2008-11 Impact factor: 2.205
Authors: Mari M Kitahata; Benigno Rodriguez; Richard Haubrich; Stephen Boswell; W Christopher Mathews; Michael M Lederman; William B Lober; Stephen E Van Rompaey; Heidi M Crane; Richard D Moore; Michael Bertram; James O Kahn; Michael S Saag Journal: Int J Epidemiol Date: 2008-02-08 Impact factor: 7.196
Authors: Jose R Castillo-Mancilla; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Ryan P Coyle; Christopher D Schneck; Mary Morrow; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson; Jose R Castillo-Mancilla Journal: AIDS Behav Date: 2019-12
Authors: Ellen F Eaton; Ashutosh Tamhane; Thibaut Davy-Mendez; Richard D Moore; W Christopher Mathews; Michael S Saag; Michael J Mugavero; Christina M Wyatt; Orlando M Gutierrez Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Robert S Rosenson; Lisandro D Colantonio; Greer A Burkholder; Ligong Chen; Paul Muntner Journal: J Am Heart Assoc Date: 2018-12-18 Impact factor: 5.501
Authors: Melanie Stecher; Philipp Schommers; Christian Kollan; Matthias Stoll; Frieder Kuhlendahl; Hans-Jürgen Stellbrink; Jan-Christian Wasmuth; Christoph Stephan; Laura Hamacher; Clara Lehmann; Christoph Boesecke; Johannes Bogner; Stefan Esser; Carlos Fritzsche; Annette Haberl; Dirk Schürmann; Olaf Degen; Heinz-August Horst; Christian Hoffmann; Björn Jensen; Carolynne Schwarze-Zander; Martin Platten; Gerd Fätkenheuer; Daniel Schmidt; Barbara Gunsenheimer-Bartmeyer; Jörg Janne Vehreschild Journal: Infection Date: 2020-07-01 Impact factor: 3.553
Authors: Anne K Monroe; Matthew E Levy; Alan E Greenberg; Jeanne C Keruly; Richard D Moore; Michael A Horberg; Paige Kulie; Bernadine S Mohanraj; Princy N Kumar; Amanda D Castel Journal: Open Forum Infect Dis Date: 2021-07-27 Impact factor: 3.835
Authors: Marta Ruiz-Algueró; Victoria Hernando; María Riero; José Ramón Blanco Ramos; Miguel Alberto de Zarraga Fernández; Pepa Galindo; Alexandre Pérez-González; Asunción Díaz; Inés Suárez-García; Inma Jarrín Journal: J Clin Med Date: 2022-03-29 Impact factor: 4.241